Clinical Trials List
2016-11-01 - 2022-10-28
Phase III
Recruiting6
ICD-10C61
Malignant neoplasm of prostate
ICD-9185
Malignant neoplasm of prostate
A Randomized, Double-blind, Placebo Controlled Phase III Study of Darolutamide (ODM-201) Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer
-
Trial Applicant
COVANCE TAIWAN SERVICES LIMITED
-
Sponsor
Bayer AG.
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Audit
None
The Actual Total Number of Participants Enrolled
10 Recruiting
Audit
None
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
Audit
None
Taiwan National PI
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
7 Recruiting
Audit
None
Co-Principal Investigator
Audit
CRO
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
48 participants
-
Global
1300 participants
